Cabergoline treatment for surgery-naïve non-functioning pituitary macroadenomas

Area of Science:

• Endocrinology
• Neurosurgery
• Oncology

Background:

• Non-functioning pituitary adenomas (NFPAs) are typically treated with surgery, radiation, medication, or observation.
• Cabergoline, a dopamine agonist, has been explored for residual NFPAs post-surgery.
• This research evaluates cabergoline's effectiveness as an initial therapy for NFPAs.

Purpose of the Study:

• To investigate the efficacy of cabergoline as a primary treatment for surgery-naive patients with non-functioning pituitary adenomas (NFPAs).

Main Methods:

• A retrospective cohort study included 25 surgery-naive patients with NFPAs (≥10 mm).
• Patients received cabergoline (≥1 mg/week) for at least 24 months; those with chiasmal damage were excluded.
• Tumor size changes (shrinkage or growth ≥2 mm) were assessed via MRI, alongside symptom and hormonal data.

Main Results:

• Twenty-five patients received cabergoline as primary therapy, with a mean follow-up of 4.6 years.
• Tumor size decreased in 20% (5/25), remained stable in 48% (12/25), and increased in 32% (8/25).
• Tumor enlargement was associated with larger initial adenoma size and longer follow-up; two patients required surgery.

Conclusions:

• Primary cabergoline treatment is a viable option for carefully selected non-functioning pituitary adenoma patients.
• This approach is particularly suitable for NFPAs where there is no immediate threat to vision.